11A
GSK icon

10-15 Associates’s GSK GSK Stock Holding History

10-15 Associates’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$12.8M Sell
271,410
-6,058
-2% -$304K 2.48% 17
2020
Q2 		$14.1M Buy
277,468
+2,630
+1% +$135K 2.85% 8
2020
Q1 		$13M Buy
274,838
+17,876
+7% +$954K 3.03% 6
2019
Q4 		$15.1M Buy
256,962
+2,894
+1% +$161K 2.85% 7
2019
Q3 		$13.6M Buy
254,068
+2,866
+1% +$147K 2.79% 8
2019
Q2 		$12.6M Buy
251,202
+5,813
+2% +$292K 2.73% 11
2019
Q1 		$12.8M Buy
245,389
+6,923
+3% +$346K 2.75% 12
2018
Q4 		$11.4M Sell
238,466
-431
-0.2% -$21.2K 2.79% 12
2018
Q3 		$12M Buy
238,897
+5,366
+2% +$273K 2.69% 11
2018
Q2 		$11.8M Buy
233,531
+8,822
+4% +$444K 2.64% 15
2018
Q1 		$11M Buy
224,709
+7,303
+3% +$340K 2.61% 16
2017
Q4 		$9.64M Buy
217,406
+6,730
+3% +$311K 2.31% 19
2017
Q3 		$10.7M Buy
210,676
+18,442
+10% +$936K 2.7% 13
2017
Q2 		$10.4M Buy
192,234
+2,061
+1% +$110K 2.91% 11
2017
Q1 		$10M Buy
190,173
+11,398
+6% +$578K 2.74% 12
2016
Q4 		$8.61M Buy
178,775
+9,909
+6% +$489K 2.41% 15
2016
Q3 		$9.1M Buy
168,866
+1,756
+1% +$96.3K 2.53% 13
2016
Q2 		$9.05M Buy
167,110
+12,712
+8% +$670K 2.6% 10
2016
Q1 		$7.83M Sell
154,398
-460
-0.3% -$22.9K 2.43% 10
2015
Q4 		$7.81M Buy
154,858
+26,257
+20% +$1.34M 2.27% 12
2015
Q3 		$6.18M Buy
128,601
+1,074
+0.8% +$55.9K 2.12% 18
2015
Q2 		$6.64M Buy
127,527
+1,927
+2% +$108K 2.06% 17
2015
Q1 		$7.25M Buy
125,600
+5,220
+4% +$299K 2.42% 16
2014
Q4 		$6.43M Buy
+120,380
New +$6.73M 2.06% 19

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

10-15 Associates's GSK Position: Q3 2020 in Review

10-15 Associates reduced its GSK (GSK) stake by 2.2% in Q3 2020, selling an estimated $304K and leaving 271,410 shares worth $12.8M. The position accounts for 2.48% of the portfolio, ranked #17.

10-15 Associates first reported a position in GSK in Q4 2014 and has held it in 24 quarters since. The position peaked at $15.1M in Q4 2019. 827 funds tracked by Wall St. Rank hold GSK as of Q3 2020.

  • 10-15 Associates held 271,410 shares of GSK worth $12.8M as of Q3 2020.
  • 10-15 Associates sold 6,058 GSK shares in Q3 2020, an estimated $304K.
  • GSK made up 2.48% of 10-15 Associates's portfolio in Q3 2020, its #17 holding.
  • 10-15 Associates first reported a position in GSK in Q4 2014 and has held it in 24 quarters since.
  • 10-15 Associates's GSK position peaked at $15.1M in Q4 2019.
  • 827 funds tracked by Wall St. Rank held GSK as of Q3 2020.

Based on 10-15 Associates's 13F filing for Q3 2020, filed 13 Oct 2020.